I wonder if ANDS recent woes , including the departure of the CEO , might be related to recent research showing that TLR7 activation is implicated in lupus. ANA 975 (HCV) and one of their anti-cancer candidates are TLR7 agonists. This links to a recent article posted by PL1 on iHub PPHM.
A PubMed search on TLR and lupus shows several papers over the past year or so implicating TLRs , in particular TLR7. Of couse ANDS should have the expertise to develop the appropriate antagonists , as well , so maybe the news isn't all bad. ;-)
Market Data 
Markets 
AI
